Cell Therapy without the Cells
GigaMune is a San Francisco biotechnology company developing a pipeline of in vivo cell therapies for cancer and inherited blood disorders.
New treatments such as chimeric antigen receptor (CAR)-T cell therapy are efficacious but manufacturing bottlenecks decrease access for patients.
Our vision is to solve the manufacturing bottleneck by infusing virus-like gene delivery particles directly into patients.
Serial biotechnology entrepreneur with exits at Natera & GigaGen. Expert in applied molecular & computational genomics. PhD & postdoc at Stanford. MBA from UC Berkeley.
Expert in cell engineering and virus like particle delivery. PhD from UCSF and postdoc at Stanford.
Translational immunology professor & clinical practice in cell therapy at Stanford. Founder at GigaGen. MD/PhD at Stanford and Harvard.
World-renowned algorithm developer for bioinformatics (MUSCLE, USEARCH). Recently published methods for searching quadrillions of nucleotides in Nature.
Yoong Wearn Lim
Expert in artificial intelligence for drug discovery. PhD from UC Davis and postdoc at Genentech.
Senior scientist in therapeutic protein screening & design. Postdoc at Stanford and PhD Oxford.
Software & wetware for discovery of viral envelopes, cell-tropic antibody fragments, and CARs
The best in vivo gene delivery particles and CAR-T therapies require very specific molecular targeting. But most drug developers rely on older technologies.
We are using powerful algorithms to search and analyze quadrillions of nucleotides to design in vivo gene delivery particles with exquisite targeting capabilities.
In vivo Cell Therapies for Cancer & Hereditary Blood Disorders
GigaMune is developing in vivo cell therapies for multiple myeloma, acute myeloblastic leukemia (AML), and inherited blood disorders such as sickle cell disease.
In addition to improving access, in vivo cell therapy does not require lymphodepletion, which is associated with medical risks and infertility.
953 Indiana St.
San Francisco, CA 94107